Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.0K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the Impact of the COVID-19 Pandemic on Pediatric Asthma Incidence.

The journal of allergy and clinical immunology. In practice·2025
Same author

A pediatric randomized, controlled trial of German cockroach subcutaneous immunotherapy.

The Journal of allergy and clinical immunology·2024
Same author

Viral Infections and Wheezing in Preschool Children.

Immunology and allergy clinics of North America·2022
Same author

Prevention and treatment of recurrent viral-induced wheezing in the preschool child.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2020
Same author

Characterization of asthma endotypes: implications for therapy.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2016
Same author

The use of anti-IgE therapy beyond allergic asthma.

The journal of allergy and clinical immunology. In practice·2015

Related Experiment Video

Updated: Apr 27, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K

Promising future therapies for asthma.

Jeffrey R Stokes1

  • 1Division of Allergy and Immunology, Creighton University Medical Center, 601 N 30th St, Suite 3M-100, Omaha, NE 68131, United States.

International Immunopharmacology
|June 25, 2014
PubMed
Summary

New asthma treatments focus on improving bronchodilation and reducing airway inflammation. Targeted therapies, like monoclonal antibodies for eosinophilic asthma, offer promising future options for patients.

Area of Science:

  • Pulmonology and Respiratory Medicine
  • Immunology
  • Pharmacology

Background:

  • Asthma impacts over 300 million globally, with increasing prevalence in developed nations.
  • Current asthma management targets airway inflammation and obstruction.
  • Existing treatments include inhaled corticosteroids combined with long-acting bronchodilators.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for asthma.
  • To highlight advancements in bronchodilation and anti-inflammatory approaches.
  • To discuss novel targeted therapies for specific asthma phenotypes.

Main Methods:

  • Review of current pharmacological treatments for asthma.
  • Analysis of emerging therapies including inhaled phosphodiesterase inhibitors and bronchial thermoplasty.
Keywords:
AsthmaCytokinesLABALAMA

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

619

Related Experiment Videos

Last Updated: Apr 27, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

619

  • Evaluation of monoclonal antibody efficacy in eosinophilic asthma targeting cytokines like IL-4, IL-5, and IL-13.

    • Main Results:

    • Combination therapies (e.g., ultra-long acting beta2 agonists, long-acting muscarinic agonists with inhaled corticosteroids) improve bronchodilation.
    • Inhaled phosphodiesterase inhibitors show potential for improved bronchodilation and reduced inflammation.
    • Monoclonal antibodies targeting IL-4, IL-5, and IL-13 have demonstrated positive outcomes in eosinophilic asthma.

    Conclusions:

    • Advances in understanding asthma pathophysiology are driving the development of more targeted therapies.
    • Future asthma management may involve a broader range of treatment options, including biologics.
    • The development of directed therapies promises improved clinical outcomes for a growing patient population.